Showing results (111-120 of 154) with videos related to

Sort By:
Pageof 16
Leukemia & Lymphoma|April 20, 2022
A multi-arm phase Ib/II study designed for rapid, parallel evaluation of novel immunotherapy combinations in relapsed/refractory acute myeloid leukemiaNicholas J Short, Gautam Borthakur, Naveen Pemmaraju, et al.
Nature|March 16, 2023
The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemiaGhayas C Issa, Ibrahim Aldoss, John DiPersio, et al.
Leukemia|June 18, 2020
Phase II trial of CPX-351 in patients with acute myeloid leukemia at high risk for induction mortalityGhayas C Issa, Hagop M Kantarjian, Lianchun Xiao, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 26, 2024
Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory FLT3-Mutated AMLNicholas J Short, Naval Daver, Courtney D Dinardo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 16, 2023
Phase I Results of Bromodomain and Extra-Terminal Inhibitor PLX51107 in Combination with Azacitidine in Patients with Relapsed/Refractory Myeloid MalignanciesJayastu Senapati, Warren C Fiskus, Naval Daver, et al.
Blood Cancer Journal|June 29, 2023
A Phase I study of Milademetan (DS3032b) in combination with low dose cytarabine with or without venetoclax in acute myeloid leukemia: Clinical safety, efficacy, and correlative analysisJayastu Senapati, Muharrem Muftuoglu, Jo Ishizawa, et al.
Blood Advances|May 27, 2026
Long-Term Outcomes of Azacitidine, Venetoclax and Gilteritinib in Newly Diagnosed FLT3-Mutated AMLNicholas J Short, Hagop M Kantarjian, Naval G Daver, et al.
Blood|November 5, 2025
Rapid clonal selection within early hematopoietic cell compartments presages outcome to ivosidenib combination therapySven Turkalj, Felix A Radtke, Bilyana Stoilova, et al.
British Journal of Haematology|September 22, 2025
MECOM fusion partner and bone marrow blast percentage influence outcomes of patients with MECOM rearranged acute myeloid leukaemiaWei-Ying Jen, Guilin Tang, Eitan Kugler, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 8, 2025
Azacitidine, Venetoclax, and Magrolimab in Newly Diagnosed and Relapsed Refractory Acute Myeloid Leukemia: Phase Ib/II Study and Correlative AnalysisNaval Daver, Jayastu Senapati, Hagop M Kantarjian, et al.
Pageof 16